Compare BSET & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSET | TNYA |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.9M | 168.2M |
| IPO Year | 1995 | 2021 |
| Metric | BSET | TNYA |
|---|---|---|
| Price | $18.96 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 27.9K | ★ 2.0M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 163.06 | 54.96 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $50.97 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $0.53 |
| 52 Week High | $22.26 | $2.35 |
| Indicator | BSET | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 43.50 |
| Support Level | $18.78 | $0.65 |
| Resistance Level | $20.81 | $0.81 |
| Average True Range (ATR) | 0.66 | 0.04 |
| MACD | -0.19 | -0.00 |
| Stochastic Oscillator | 1.98 | 28.61 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.